Compare Coursera Inc (COUR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Viatris Inc — how do they compare? Coursera Inc trades at $5.61 (market cap $1.64B), while Viatris Inc trades at $16.52 (market cap $18.99B). The key difference: Viatris Inc is far larger — about 11.6× Coursera Inc's market cap, and Viatris Inc pays a 2.94% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| COUR | VTRS | |
|---|---|---|
Market Cap | $1.64B | $18.99B |
Sector | Consumer Staples | Health |
52-Week High | $12.70 | $17.39 |
52-Week Low | $5.09 | $8.74 |
Enterprise Value | $890.21M | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.67, down 0.7% on the day, with technical indicators showing a bearish trend. The company reported Q1 2026 earnings of $0.07 per share, missing estimates of $0.09, but revenue growth remains positive, reaching $757.5 million in 2025. Recent news highlights the completion of the Udemy merger and a $500 million share repurchase program, while analyst sentiment is mixed with a consensus price target of $8.00.
The outlook for COUR is cautiously optimistic, driven by potential synergies from the Udemy merger and steady revenue growth, though profitability challenges and competitive pressures pose risks. With a 52.94% buy rating from analysts and a 38.5% upside to the consensus target, the stock offers growth potential, but investors should monitor execution on cost management and integration success.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
